GlassScriptPhysician profile
Job Jacob
NPI 1053377101
$3,763.15
in general payments reported to CMS, 2019-2025
26 companies · $883 in 2025
The $883 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $368 · 2021: $577 · 2022: $340 · 2023: $601 · 2024: $36.10 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $806.39 | 2019-2025 | |
| Boston Scientific Corporation | $476.81 | 2019-2022 | |
| Pfizer INC. | $327.68 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.10 | 2019-2024 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $250.60 | 2019-2021 | |
| Evoke Pharma, INC. | $214.53 | 2022-2024 | Gimoti |
| Madrigal Pharmaceuticals | $194.50 | 2025 | Rezdiffra |
| Allergan, INC. | $179.20 | 2019-2020 | |
| Ethicon US, LLC | $150.00 | 2025 | Echelon Endopath |
| Aimmune Therapeutics, INC. | $149.27 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $123.69 | 2019-2022 | |
| Medtronic, INC. | $88.34 | 2022 | |
| Celltrion USA INC. | $74.50 | 2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $66.54 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $54.66 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $49.99 | 2021-2023 | Stelara |
| Genzyme Corporation | $47.04 | 2022-2023 | |
| Celgene Corporation | $39.01 | 2023 | Zeposia |
| Lilly USA, LLC | $36.93 | 2025 | Omvoh |
| Echosens North America, INC. | $34.51 | 2019-2021 | |
| Ucb, INC. | $26.91 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $25.84 | 2025 | Dupixent |
| Olympus America INC. | $14.39 | 2019 | |
| Redhill Biopharma INC. | $13.85 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.09 | 2020 | |
| Braintree Laboratories, INC. | $12.78 | 2023 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Job Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.